<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Data from experimental studies suggest that <z:chebi fb="27" ids="27300">vitamin D</z:chebi> receptor activation exerts anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> effects on virtually <z:hpo ids='HP_0000001'>all</z:hpo> steps of <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Epidemiological data support an inverse association of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> serum levels and <z:chebi fb="27" ids="27300">vitamin D</z:chebi> receptor polymorphisms with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> incidence and mortality </plain></SENT>
<SENT sid="2" pm="."><plain>Based on this promising rationale for use of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> and its analogues in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> prevention and treatment, several interventional studies have been initiated and partially published </plain></SENT>
<SENT sid="3" pm="."><plain>Trials with <z:chebi fb="27" ids="27300">vitamin D</z:chebi> were mainly organized for the prevention of fracture in elderly people, usually in association with calcium supplements </plain></SENT>
<SENT sid="4" pm="."><plain>Prevention studies with <z:chebi fb="27" ids="27300">vitamin D</z:chebi> have rarely been done in the context of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> to evaluate a protective effect on <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Findings from prospective cohort studies on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> risk and on mortality constitute pieces of evidence strong enough to consider that previous randomized controlled trials (RCTs) of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> use and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> may not have correctly addressed the question, and that new randomized trials should be organized </plain></SENT>
<SENT sid="6" pm="."><plain>The reasons are due to several unsolved issues including selection of the effective dose, varying baseline levels of subjects before randomization, compliance with the intervention, contamination of the placebo group (i.e., intake of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> supplements by subjects allocated to the placebo group) and unknown effective lag time between start of the intervention and disease <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The present review summarizes the existing knowledge on <z:chebi fb="27" ids="27300">vitamin D</z:chebi> RCTs and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>In addition we also briefly describe the design of some ongoing trials on <z:chebi fb="27" ids="27300">vitamin D</z:chebi> supplementation and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>